Canada: Health Canada Invites Public Comments On New Post-Market Reporting Regulations

Last Updated: August 16 2018
Article by Ben Pearson

The medical device industry in America and perceived shortcomings in the US Food and Drug Administration's ("FDA") approval process have recently come under scrutiny in popular media.

An often-cited concern with the FDA's approval process relates to the 510(k) pathway, whereby a medical device may reach the market with a lesser amount of clinical testing. Through this regulatory pathway, a medical device may be approved if the manufacturer can demonstrate that their device is "substantially equivalent" to another device already on the market.

In this article, we take a look at the current regulatory regime in Canada as it pertains to medical devices, as well as what Health Canada is doing to implement regulatory reforms.

What is a Medical Device?

In Canada, medical devices are regulated by the Medical Device Bureau ("MDB") of Health Canada's Therapeutic Products Directorate ("TPD") in accordance with the Medical Device Regulations  (the "Regulations"). Enacted on May 7, 1998, pursuant to the Food and Drugs Act, the Regulations  define a medical device as "an instrument, apparatus, contrivance or other similar article, or an in vitro reagent, including a component, part or accessory of any of them, that is manufactured, sold or represented for use in":

(a)  diagnosing, treating, mitigating or preventing a disease, disorder or abnormal physical state, or any of their symptoms;

(b)  restoring, modifying or correcting body structure or the functioning of any part of the body;

(c)  diagnosing pregnancy;

(d)  care during pregnancy or at or after the birth of the offspring, including caring for the offspring; or

(e)  preventing conception.

The Regulations apply only to medical devices for use in humans and not animals.

Medical devices are classified according to Health Canada's risk-based system. Devices are assigned one of four device classifications according to a set of 16 rules set out as Schedule 1 to the Regulations. In vitro diagnostic devices (i.e. devices and accessories used to perform tests on bodily samples) are subject to their own set of 9 rules. Each rule defines the classification based on how it is used, whether it is invasive, what system of the body it primarily affects, and whether energy, either electrical or other, may be used and/or transferred in a potentially hazardous way.

Class I represents the lowest risk to the patient while Class IV represents the highest risk. Pursuant to the Regulations, where a medical device can be classified into more than one class, the class representing the higher risk applies. Examples of each class are set out in Table 1, below:

Class

Examples

Class I

Reusable surgical instruments, dressing and bandages, toothbrushes, wheelchairs and hospital beds.

Class II

Single use surgical instruments, short-term catheters, contact lenses, blood pressure monitors, MRI equipment, and dentures.

Class III

Long-term indwelling catheters, intraocular lens, pancreatic stents, hip implants, glucose monitors, ventilators, and intrauterine contraceptive devices (IUDs)

Class IV

Intra-aortic balloon catheters, coronary stents, pacemakers, implanted spinal cord stimulators for pain relief, mechanical heart valves, and fetal pH monitor

How are Medical Devices approved in Canada?

The risk-based classification system determines the applicable approval process – with more demanding approval requirements for higher-risk devices.

Class I medical devices do not require licensing for the actual device. However, the Regulations require that any person, partnership or association involved in the importation or sale of such devices hold a Medical Device Establishment License ("MDEL"). An MDEL certifies that an establishment involved in the Canadian distribution of a Class I device meets the applicable standards of manufacture, but requires no evidentiary or clinical documentation.

In addition to basic contact and manufacturing information, an application for an MDEL requires an attestation by a senior official that the establishment has procedures in place to assure compliance with safety requirements and to protect the public should a problem with a device be identified. MDEL holders must submit an application for the review of their license on a yearly basis.

For Class II, III or IV devices, the actual device requires licensing before it can be sold in or imported into Canada. Manufacturers of these classes of devices must obtain a Medical Device License ("MDL") as certification of the device's quality, safety and efficacy. Applications for an MDL require a quality management system certificate issued by a Health Canada Registrar.

As lower-risk devices, Class II devices must provide an attestation by a senior official of the manufacturer of the device's compliance with safety and effectiveness requirements, but do not require clinical evidence.

For a Class III device application, summary evidentiary information must be provided. Approvability requirements for Class III devices also include:

  • a description of the materials used in its manufacture and packaging;
  • sale numbers in countries other than Canada and a summary of problems reported therein;
  • studies relied upon to ensure compliance with safety and effectiveness requirements; and
  • all published reports dealing with the use, safety and effectiveness of the device.

As they pose the highest risk, licensing applications for devices under Class IV are the most demanding and require detailed evidence as to their safety. In addition to the application requirements for Class III devices, licensing of Class IV devices notably require the following:

  • a risk assessment comprising an analysis and evaluation of the risks, and the risk reduction measures adopted to satisfy safety and effectiveness requirements;
  • a quality plan setting out the specific quality practices and resources;
  • the manufacturing process of the device;
  • detailed information of the studies relied on to ensure compliance with safety and effectiveness requirements (e.g. pre-clinical and clinical studies, process validation studies and literature studies); and
  • objective evidence of the biological safety of devices incorporating human or animal tissue.

Does Canada have a 510(k) Equivalent?

In Canada, there is no equivalent to the FDA's 510(k) process. The 510(k) clearance pathway requires that a sponsor demonstrate that there is substantial equivalence to products already approved in the US market and that the difference between the "new" and existing device is immaterial. This regulatory pathway is available for both Class I and II medical devices in the US.

In Canada, all devices except Class I require a MDL before they can be sold. Therefore, Health Canada's requirements for Class II, III and IV devices are higher than the standards employed in the US.

What Post-market safety requirements exist?

While much recent discussion of the medical device industry has focused on pre-market approval process, a potentially larger issue exists in the under-reporting of adverse events. An adverse event is any unintentional, unfavourable clinical sign, symptom, or complication occurring as a result of treatment.

David Kessler, the FDA Commissioner from 1990 to 1997, notes that while a system for reporting complications exists there is "tremendous underreporting because it's a voluntary system" Rita Redberg, the Editor of Internal Medicine for the Journal of the American Medical Association, echoes this concern:

If a physician observes an adverse event, they do not have to report it. The only bodies that are required to report adverse events are the companies. It's estimated that only 3-4% of adverse events are reported to the FDA.

As  in the US, the Regulations  in Canada provide that device manufacturers must report adverse events to Health Canada. However, aside from obligations imposed on manufacturers, the reporting of adverse events is not mandatory. Health care providers are under no obligation to report adverse events to the FDA or Health Canada and would be well-served by a redesign of the regulatory framework so as to clarify and facilitate reporting of adverse events.

It has been estimated that only 5% of all adverse drug reactions and adverse events are reported to Health Canada. Even with a stronger pre-market approval process, this begs the question of how Health Canada and other regulatory bodies can adequately regulate marketed devices in the absence of accurate statistics regarding the prevalence of adverse events.

What Steps is Health Canada Taking?

Health Canada has been actively taking steps to reform the regulatory framework available to health care providers. On June 15, 2018, Health Canada published proposed regulations in the Canada Gazette, Part I which seek to amend the Food and Drug Regulations and Medical Devices Regulations to require hospitals to report serious adverse drug reactions and adverse medical device events.

Under the proposed regulations, hospitals would be required to report all adverse events to Health Canada, in writing, within 30 days of the incident. While the proposed regulations would only require "serious" adverse drug reactions to be reported, no such limitation is placed on medical device incidents. 

For now, these regulations would only apply to hospitals and not to other healthcare facilities or providers. Canadians and other stakeholders have been invited to provide comments on this regulatory proposal by August 29, 2018. 

Read the original article on GowlingWLG.com.

This article was co-authored by Karl Racine, a Summer Law Student at Gowling WLG's Ottawa office.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
McCarthy Tétrault LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
McCarthy Tétrault LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions